

# SPHHP Research Activities Newsletter

University at Buffalo

August 2018

## In the News

### Congratulations to the Following Awardees!



**Jeanne Langan**, Assistant Professor of Rehabilitation Science, is PI, on a continuation award from the Eunice Kennedy Shriver National Institute of Child Health & Human Development/NIH for the project entitled, *A functional Upper Limb Training and Assessment Tool to Enhance Efficacy and Scalability of Rehabilitation in Ecological Environments*. This research incorporates smart Devices and 3D printing to create patient-centered rehabilitation devices that are scalable.



**Lucia Leone**, Assistant Professor of Community Health and Health Behavior, and **Jennifer Temple**, Associate Professor of Exercise and Nutrition Sciences, are Co-Is on a continuation award from the Eunice Kennedy Shriver National Institute of Child Health & Human Development/NIH (Leonard Epstein, PI, Pediatrics) for the project entitled, *Can Reinforcing Alternatives to Food Prevent Weight Gain in Children?* The project will continue to study individual differences in reinforcing value of food and alternatives to food in the home environment, providing the first test of the potential protective effect of strong alternative reinforcers to food for risk of weight gain in children.



**Ekaterina Noyes**, Professor of Epidemiology and Environmental Health, is PI on a new award from the National Cancer Institute/NIH for the project entitled, *Problem Solving Skills Training in Adult Cancer Survivors: Bright IDEAS-AC*. The goal of this study is to assess the feasibility and acceptability of problem solving skills training among colorectal cancer survivors. These results will be used to develop and test a novel intervention (Bright IDEAS- AC) to help improve health and function of cancer survivors by increasing utilization of cancer survivorship plans in a multi-site randomized pragmatic trial.



**Heather Orom**, Associate Professor of Community Health and Health Behavior, is PI on a continuation award from the National Cancer Institute/NIH for the project entitled, *"Don't Know" Responses to Risk Perception Questions: Identifying Mechanisms and Solutions*. The study continues to explore reasons why a significant proportion of people do not know their risk for two highly preventable diseases, Type 2 diabetes and colorectal cancer, despite the proliferation of risk-based prevention messages about these diseases.



**John Violanti**, Research Professor of Epidemiology and Environmental Health, is PI on a continuation award from the National Institute for Occupational Safety and Health/CDC for the project entitled, *Stressors and Cardio-Metabolic Disease in Police: A 12-Year Longitudinal Study*. The research continues to examine the impact of occupational stressors on early signs of cardiovascular and metabolic diseases in police officers to advance knowledge and prevention efforts in the field. **Jean Wactawski-Wende**, Dean of SPHHP and SUNY Distinguished Professor of Epidemiology and Environmental Health, is Co-Investigator.



**Jean Wactawski-Wende**, Dean of the SPHHP and SUNY Distinguished Professor of Epidemiology and Environmental Health, is PI on a continuation award from the National Institute of Dental and Craniofacial Research/NIH entitled, *Oral Microbiome and Periodontitis: A Prospective Study in Postmenopausal Women*. The study continues to characterize oral bacteria that are associated with periodontal disease severity and progression in older women. In the future, this information could inform strategies for prevention and treatment of periodontal disease. **Michael LaMonte** and **Amy Millen** are Co-Investigators.

#### Inside this issue:

In the News	1-2
Grant Clinic	2
NIH Funding:	
Limited	3
RFA	3-7
PAR	7-8
PA	8
Words to Live By	8



**Guan Yu**, Assistant Professor of Biostatistics, is Co-I on a new award from the National Institute of Dental & Craniofacial Research/NIH (Jill Kramer, PI, Oral Biology), for the project entitled, *Analysis of the Role of IgM in Sjogrens Syndrome (SS)*. The study seeks to identify the B cells subsets responsible for autoreactive IgM production in SS patients and to determine whether IgM is protective in the context of SS disease.

Dr. Yu also is Co-I on a continuation award from the National Cancer Institute/NIH (Yun Wu, PI; Biological Engineering) for the project entitled, *Noninvasive Early Detection of Circulating RNA for Lung Cancer Early Detection and Prognosis*. The study continues to develop and validate a biochip which may assist in lung cancer screening, early detection and prognosis in obtaining detailed insights in basic lung cancer biology.

## Grant Clinic

### NIH Extramural Repayment Loan Programs (LRPs) Application Period will be Open **09/01/18 – 11/15/18**

The LRPs are a set of programs established by Congress and designed to recruit and retain highly qualified health professionals into biomedical or biobehavioral research careers. Qualified health professionals who contractually agree to engage in NIH mission-relevant research for at least two years initially, and who agree to engage in such research for an average of at least 20 hours per week based on a 40-hour work week, are invited to apply. The award will repay up to \$35,000 annually of a researcher's qualified educational debt. Research funding from NIH is not required to participate in the Extramural LRPs. Additional information about each LRP is provided at <https://www.lrp.nih.gov/>

#### [NOT-OD-18-208](#)

### **FAQs Available for Developing Interventions for Health-Enhancing Physical Activity (PAR-18-307; R21/R33) and Testing Interventions for Health-Enhancing Physical Activity (PAR-18-324, R01)**

NIH has developed a list of Frequently Asked Questions (FAQs) in response to discussions with various applicants regarding permissible research plans under these FOAs. The FAQs are posted at [2018 PAR-18-307](#) [PAR-18-327](#)  
[FAQs](#)

#### [NOT-HS-18-012](#)

### **Confidentiality in AHRQ-Supported Research**

AHRQ would like to remind the research community of its policy regarding Confidentiality in AHRQ-supported research. The AHRQ confidentiality statute provides that “no information, if an establishment or person supplying the information or described in it is identifiable, obtained in the course of activities undertaken or supported under this subchapter may be used for any purpose other than the purpose for which it was supplied unless such establishment or person has consented (as determined under regulations of the Director) to its use for such other purpose. Please see the Notice for additional information.

#### [NOT-DA-18-015](#)

### **NIDA Division of Neuroscience and Behavior will Give High Programmatic Priority to Opioid Related Basic Research**

NIDA strongly encourages potential applicants to submit applications that address the opioid epidemic to existing FOAs. This notice is in effect until August 2019.

### **Notices of Intent to Publish a Funding Opportunity Announcement**

NIH has provided the following notices to allow potential applicants sufficient time to develop competitive applications:

[NOT-CA-18-078](#); [NOT-CA-18-179](#) Tobacco Cessation Intervention Among People Living with HIV/AIDS (R01; R21) anticipated release Summer 2018; Due Date Winter 2018

[NOT-DA-18-024](#) The National Drug Abuse Treatment Clinical Trials Network (UG1, clinical trial optional); anticipated release August 2018; due date November 2018

[NOT-HL-18-632](#) Disparities Elimination through Coordinated Interventions to Prevent and Control Heart and Lung Disease Risk (DECIPHER); anticipated release fall 2018; due date winter 2019

[NOT HS-18-011](#) Promote Screening and Management of Unhealthy Alcohol Use in Primary Care (R18); anticipated release date and due date unknown at this time

[NOT-OD-18-174](#) Predoctoral Training in Advanced Data Analytics for Behavior and Social Sciences Research (BSSR) Institutional Research Training Program; anticipated release October 2018; due date May 2019

## NIH Funding Opportunities: **Limited Submissions**

If you are interested in applying to any of the **limited submissions** listed below, please provide the OVPRED with notification through the [Limited Submissions Mailbox](#) at least 60 days prior to the sponsor's submission deadline before proceeding with an application. The limited submission program is managed by Dr. Kenneth Tramosch on behalf of the OVPRED. He may be contacted at [kmt1@buffalo.edu](mailto:kmt1@buffalo.edu) or by phone at 645-3321 for any questions or advice about the limited submission process.

[RFA-ES-18-002 \(P42\)](#), clinical trial optional

### **Superfund Hazardous Substance Research and Training Program**

This program supports problem-based, solution-oriented research Centers that consist of multiple, integrated projects representing both the biomedical and environmental science and engineering disciplines; as well as cores tasked with administrative (which includes research translation), data management and analysis, community engagement, research experience and training coordination, and research support functions. *Only one application per institution is allowed.*

**Application Due Date:** December 19, 2018

## NIH Funding Opportunities: Requests for Applications (RFA)

### September Due Dates

[RFA-RM-18-008 \(DP2\)](#) - clinical trial optional

### **NIH Directors New Innovator Award Program**

The [NIH Director's New Innovator Award](#) supports early stage investigators of exceptional creativity who propose highly innovative new research approaches with the potential to produce a major impact on broad, important problems in biomedical or behavioral research. Applications from individuals with diverse backgrounds and in any topic relevant to the broad mission of NIH are welcome. **Application Due Date:** September 10, 2018

[RFA-ES-18-008 \(R43\)](#), clinical trial not allowed

### **Novel Approaches for Characterizing Exposure and Response to Engineered Nanomaterials**

SBIR applications are sought to develop and/or adapt novel technologies to enable the characterization of human exposures to engineered nanomaterials (ENMs) and to monitor or assess ENMs in diverse media ranging from biological samples to air and water. **Application Due Date:** September 11, 2018

[RFA-RM-18-007 \(DP1\)](#) – clinical trial optional

### **NIH Director's Pioneer Award**

This award supports individual scientists of exceptional creativity who propose highly innovative and potentially transformative approaches to major challenges in the biomedical or behavioral sciences towards the goal of enhancing human health. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator's research program or elsewhere.

**Application Due Date:** September 14, 2018

[RFA-CA-18-026 \(R01\)](#) – clinical trial required

### **Improving the Reach and Quality of Cancer Care in Rural Populations**

The FOA encourages two types of applications: 1) observational research that includes pilot testing of intervention to understand and address predictors of cancer care/treatment and outcomes in rural low-income and/or underserved populations; or 2) intervention research to address known predictors of cancer care/treatment and outcomes in rural low-income and/or underserved populations. **Application Due Date:** September 19, 2018

[RFA-RM-18-009 \(R01\)](#) – clinical trial optional

### **NIH Directors Transformative Research Award**

The [NIH Director's Transformative Research Award](#) supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies.

**Application Due Dates:** September 21, 2018

[RFA-CA-18-005 \(R33\)](#) – clinical trial not allowed

### **Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research**

This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. **Application Due Dates:** September 28, 2018

[RFA-CA-18-004 \(R21\)](#) – clinical trial not allowed

**Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research**

This FOA solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens.

**Application Due Dates:** September 28, 2018

**October Due Dates**

[RFA-MH-17-604 \(R61/R33\)](#) - **Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders**

[RFA-MH-17-606 \(R33\)](#) - **Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders**

The purpose of these FOAs is to support the efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, using an experimental therapeutics approach. These FOAs support the development and testing of innovative psychosocial intervention approaches where the target and/or the intervention strategy is novel. **Application Due Dates:** October 15, 2018

[RFA-MH-17-612 \(R34\)](#)

**Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions**

This FOA encourages pilot research consistent with [NIMH's priorities](#) for: 1) effectiveness research on preventive and therapeutic interventions with previously demonstrated efficacy, for use with broader target populations or for use in community practice settings, and 2) research on the development and preliminary testing of innovative services interventions. **Application Due Dates:** October 15, 2018

[RFA-MH-18-700 \(Collaborative R01\)](#) - clinical trial and participation of two or more collaborative sites required

[RFA-MH-18-701 \(R01\)](#) – clinical trial required

**Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions**

These FOA support clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings.

**Application Due Dates:** October 15, 2018

[RFA-MH-18-704 \(R61/R33\)](#) – clinical trial required

[RFA-MH-18-705 \(R33\)](#) – clinical trial required

**Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders**

These FOAs support the efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, using an experimental therapeutics approach.

**Application Due Dates:** October 15, 2018

[RFA-MH-18-707 \(R01\)](#) – clinical trial required

**Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders**

This FOA supports confirmatory efficacy testing of non-pharmacological therapeutic and preventive interventions for mental disorders in adults and children through an experimental therapeutics approach. Trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development, effectiveness testing, or dissemination of the intervention.

**Application Due Dates:** October 15, 2018

[RFA-AG-19-005 \(R24\)](#) – clinical trial optional

**Collaborative Network to Advance Deprescribing Research for Older Adults with Multiple Chronic Conditions**

This FOA is intended to support a collaborative network to advance scientific research into techniques and outcomes of deprescribing medications for prevention and treatment of older adults with multiple chronic conditions. This network should address the scientific, safety, ethical, and logistical challenges of deprescribing trials and may incorporate focused attention to other relevant and well-justified topics, such as the risks and benefits of target medications, or alternative approaches that may substitute for the deprescribed drugs. **Application Due Date:** October 18, 2018

[RFA-AG-19-008 \(R24\)](#) – clinical trial not allowed

**Edward R. Roybal Coordinating Center**

This FOA invites applications from qualified institutions to create a Roybal Center Coordinating Center (CC), serving the needs of the Roybal Centers for Translational Research on Aging program as well as the Roybal Centers for Translational Research on Dementia Care Provider Support program. The Roybal Coordinating Center will facilitate and coordinate trans-Roybal activities. The Center will work closely with the NIA Program Officer and, in coordination with all Roybal sites, will be responsive to requests generated by key Roybal site personnel, NIA, NIH, the scientific community, and the general public. **Application Due Date:** October 18, 2018

[RFA-AG-19-006 \(P30\)](#) – clinical trial required

**Roybal Centers for Translational Research on Aging**

This FOA solicits Edward R. Roybal Centers for Translation Research in the Behavioral and Social Sciences of Aging. The purpose is to develop behavioral interventions that improve the health and well-being of people as they are aging and the capacity of institutions to adapt to societal aging. **Application Due Date:** October 18, 2018

[RFA-AG-19-007 \(P30\)](#) – clinical trial required

**Roybal Centers for Translational Research on Dementia Care Provider Support**

This FOA solicits Edward R. Roybal Centers for translational intervention development research for Alzheimer's disease and Alzheimer's disease related dementias (AD-ADRD) care provider support. The purpose is to develop behavioral interventions that improve the health, well-being and/or capacity of individuals and/or systems that provide care to persons with AD-ADRD. **Application Due Date:** October 18, 2018

[RFA-HL-19-027 \(U34\)](#) – clinical trial not allowed

**Catalyzing Innovation in Late Phase Clinical Trial Design and Statistical Analysis Plans**

The purpose of this FOA is to provide support for planning activities for late phase (phase II and beyond) single-site or multi-site investigator-initiated clinical trials that address critical clinical questions within the mission of the National Heart, Lung, and Blood Institute and that require non-traditional clinical trial designs with the opportunity for statistical novelty and/or innovation. The FOA will support the development of feasible and well-designed clinical trials utilizing consultative services provided by the Innovative Clinical Trials Resource (ICTR) (N01).

**Application Due Dates:** October 19, 2018

[RFA-AG-19-017 \(K76\)](#) – clinical trial not allowed

[RFA-AG-19-018 \(K76\)](#) – clinical trial required

**Paul B. Beeson Emerging Leaders Career Development Award in Aging**

This FOA invites early-stage physician and other health professional investigators with a commitment to aging and/or aging-related diseases to apply for this award to advance their research and leadership skills in their specialty and in the broader field of aging and geriatrics research. Candidates for this award must have received competitively awarded research support as a PD/PI at the faculty level or have otherwise leveraged faculty-level research support to develop an independent line of research. **Application Due Date:** October 24, 2018

[RFA-CA-18-019 \(R01\)](#); [RFA-CA-18-020 \(R21\)](#) - clinical trial optional

**Research Answers to NCI's Provocative Questions**

The purpose of these FOAs are to support research projects designed to solve specific problems and paradoxes in cancer research identified by the NCI Provocative Questions initiative. Each research project must be focused on addressing one particular research problem defined by one specific PQ selected from the list found in the FOAs.

**Application Due Dates:** October 30, 2018

[RFA-CA-18-021 \(R01\)](#); [RFA-CA-18-022 \(U01\)](#); [RFA-CA-18-023 \(P01\)](#); [RFA-CA-18-024 \(P50\)](#) – clinical trial optional

**Revision Applications to National Cancer Institute (NCI)-supported Awards to Include Research on the NCIs Provocative Questions**

These FOAs invite revision applications from investigators with active NCI R01, U01, P01 or P50 research grants and are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published for new applications in RFA-CA-18-019 (R01) and RFA-CA-18-020 (R21). This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. **Application Due Dates:** October 30, 2018

**November Due Dates**

[RFA-DA-19-005 \(R61/R33\)](#) – clinical trial required

**Science-Based Quality Measurement and Management Development for Opioid Use Disorder Treatment**

This FOA solicits applications proposing phased research projects, with transition milestones, to develop and rigorously test the effects of strategies to improve opioid treatment quality measures, both on changes in the measures themselves and on patient outcomes. The overall goal is to advance the field of clinical quality measurement and management in opioid use disorder treatment by generating research better aligning quality measurement with quality improvement.

**Application Due Date:** November 7, 2018

**December Due Dates**

[RFA-DK-17-024 \(R01\)](#) – clinical trial required

**Impact of the Use of Glucose Monitoring and Control Technologies on Health Outcomes and Quality of Life in Older Adults with Type 1 Diabetes (T1D)**

This FOA encourages clinical trials testing the clinical efficacy of new technology to improve glucose control, reduce hypoglycemic events and/or improve quality of life in older T1D patients (aged 65 and older).

**Application Due Dates:** December 6, 2018

[RFA-DK-18-002 \(R01\)](#) – clinical trial optional

### **Understanding Skeletal Effects of Type 1 Diabetes**

This FOA invites applications for studies to understand the effects of type 1 diabetes (T1D) on bone mass and quality and/or fracture risk. Researchers may propose investigations in newly recruited subjects or using subjects and/or samples from ongoing clinical studies of individuals with for T1D.

**Application Due Date:** December 6, 2018

## **February Due Dates**

[RFA-AG-19-015 \(R24\)](#) – clinical trial not allowed

### **High-Priority Behavioral and Social Research Networks**

This FOA invites applications to provide infrastructure support for advancing development of specific high-priority areas of behavioral and social research of relevance to aging. Network applications are limited to the following areas: (1) Mid-life Reversibility of Biobehavioral Risk Associated with Early Life Adversity, (2) Stress Measurement, (3) Reproducibility in the Social and Behavioral Sciences, (4) Life Course Health Disparities at Older Ages, (5) Genomics of Behavioral and Social Science, (6) Integrating Animal Models to Inform Behavioral and Social Research on Aging, and (7) Rural Aging. **Application Due Date:** February 1, 2019

[RFA-AG-19-016 \(R24\)](#) – clinical trial not allowed

### **High-Priority Behavioral and Social Research Networks in Alzheimer's Disease and Alzheimer's Disease Related Dementias**

This FOA invites applications to provide infrastructure support for advancing development of specific high-priority areas of behavioral and social research of relevance to Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD). Network applications are limited to the following areas: (1) AD/ADRD care and services research, and (2) the coordination of international studies conducting the Harmonized Cognitive Assessment Protocol.

**Application Due Date:** February 1, 2019

## **Multiple Due Dates**

[RFA-HL-19-023 \(T32\)](#) – clinical trial not allowed

### **T32 Training Program for Institutions That Promote Diversity**

The NHLBI's T32 Training Program is intended to support training of predoctoral and health professional students and individuals in postdoctoral training institutions with an institutional mission focused on serving health disparity populations not well represented in scientific research, with the potential to develop meritorious training programs in cardiovascular, pulmonary, and hematologic diseases, and sleep disorders. **Application Due Dates:** September 4, 2018; February 26, 2019; September 4, 2019; February 26, 2020; September 4, 2020; February 26, 2021

[RFA-HL-19-016 \(R43\)](#) – clinical trial not allowed

### **Technologies for Healthy Independent Living for Heart, Lung, Blood and Sleep Disorders**

This FOA seeks applications for the design and development of technologies to monitor health or deliver care in a real-time, accessible, effective, and minimally obtrusive way for older adults with a chronic heart, lung, blood, or sleep (HLBS) condition. These technologies may be novel sensor or monitoring systems, home-use point-of-care devices, home or mobile therapy or rehabilitation tools, or information systems and should have the goal of fostering healthy and independent living for aging adults with HLBS conditions. **Application Due Dates:** September 10, 2018; June 10, 2019; June 10, 2020

[RFA-HL-19-024 \(R25\)](#) – clinical trial not allowed

### **Short-Term Research Education Program to Increase Diversity in Health-Related Research**

The over-arching goal of this program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce by providing research experiences and related opportunities that enrich the pool of individuals from nationally underrepresented groups who will be available to compete for research opportunities in the mission areas of importance to NHLBI. This FOA will support creative educational activities with a primary focus on Research Experiences. **Application Due Dates:** September 10, 2018, February 26, 2019, September 10, 2019, February 26, 2020, September 10, 2020, February 26, 2021

[RFA-HL-19-025 \(K01\)](#) – clinical trial required; [RFA-HL-19-026 \(K01\)](#) – clinical trial not allowed

### **Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research**

These FOAs are targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. **Application Due Dates:** October 10, 2018, February 11, 2019, October 10, 2019, February 11, 2020, October 9, 2020, February 11, 2021

[RFA-HL-17-022 \(R21\)](#)

**Maximizing the Scientific Value of the NHLBI Biorepository: Scientific Opportunities for Exploratory Research**

This FOA will support meritorious exploratory research relevant to the [NHLBI mission](#) using the existing biospecimen collections that are stored in the NHLBI Biologic Specimen Repository, thereby maximizing the scientific value of the stored collections and providing researchers with an opportunity to generate preliminary data for subsequent research proposals. **Application Due Dates:** October 17, 2018; February 15, 2019; October 17, 2019

[RFA-OD-18-005 \(K01\)](#) – clinical trial not allowed

[RFA-OD-18-006 \(K01\)](#) – clinical trial required

**Mentored Research Scientist Career Development Award in Tobacco Regulatory Research**

These FOAs provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence.

**Application Due Dates:** November 8, 2018, July 19, 2019, November 8, 2019

[RFA-OD-18-007 \(K99/R00\)](#) – clinical trial not allowed

[RFA-OD-18-008 \(K99/R00\)](#) – clinical trial required

**Pathway to Independence Award in Tobacco Regulatory Research**

This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. **Application Due Dates:** November 8, 2018, July 19, 2019, November 8, 2019

[RFA-ES-16-005 \(R21\)](#)

**Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences**

This FOA supports environmental health research in which an unpredictable event provides a limited window of opportunity to collect human biological samples or environmental exposure data to understand the consequences of natural and man-made disasters or emerging environmental public health threats in the U.S. and abroad. **Application Due Dates:** Multiple due dates, please see FOA. **Expiration Date:** June 2, 2019

**NIH Funding Opportunities: Program Announcement Reviewed by an Institute (PAR)**

[PAR-18-845 \(R01\)](#); [PAR-18-846 \(R21\)](#) – clinical trial not allowed

**Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects**

These FOAs support basic research examining how Electronic Nicotine Delivery Systems (ENDS) aerosols affect normal and disease states relevant to human cells, tissues and organs. **Application Due Dates:** October 24, 2018; June 27, 2019; October 24, 2019; June 27, 2020

[PAR-18-847 \(R01\)](#); [PAR-18-848 \(R21\)](#) – clinical trial optional

**Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research**

These FOAs support studies on electronic nicotine delivery systems (ENDS) that examine population-based, clinical and applied prevention of disease, including etiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations. **Application Due Dates:** October 24, 2018; June 27, 2019; October 24, 2019; June 27, 2020

[PAR-18-869 \(R01\)](#) – clinical trial optional

**Modular R01s in Cancer Control and Population Sciences**

These FOAs provide support to research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science. **Application Due Dates:** November 7, 2018; March 6, 2019; November 7, 2019; March 6, 2020; November 6, 2020; March 8, 2021

[PAR-18-844 \(R01\)](#); [PAR-18-843 \(R21\)](#) – clinical trial not allowed

**Investigator Initiated Research in Computational Genomics and Data Science**

NHGRI seeks to fund innovative research efforts in computational genomics, data science, statistics, and bioinformatics for basic or clinical genomic sciences, and broadly applicable to human health and disease, as well as research leading to improvement of existing software or approaches demonstrated to be in broad use by the genomics community.

**Application Due Dates:** November 16, 2018; July 16, 2019; November 16, 2019; July 16, 2020; November 16, 2020; July 16, 2021

[PAR-18-840 \(D43\)](#) – clinical trial optional

**Global Infectious Disease Research Training Program**

This FOA seeks applications for the Global Infectious Disease (GID) Research Training Program from U.S. and low- and middle-income country (LMIC) institutions. The application should propose a collaborative training program that will strengthen the capacity of an LMIC institution to conduct infectious disease research.

**Application Due Date:** July 25, 2019

[PAR-18-854 \(R01\)](#) – clinical trial not allowed

**Time-Sensitive Obesity Policy and Program Evaluation**

This FOA encourages and supports research in which a unique and time sensitive opportunity has arisen to collect baseline data and then prospectively assess effectiveness of an imminent policy or program that is likely to prevent or reduce obesity in a given population (e.g. reduce energy intake, increase activity, or decrease sedentary behavior).

**Application Due Dates:** multiple dates, please refer to the FOA.

[PAR-18-857 \(R21\)](#) – clinical trial not allowed

**Diet and Physical Activity Assessment Methodology**

This FOA will support research pertinent to improving the measurements of diet and physical activity through the development of better instruments, innovative technologies, and/or applications of advanced statistical/analytic techniques.

**Application Due Dates:** Standard dates apply; **Expiration Date:** September 8, 2021

[PAR-18-864 \(UG1\)](#) – clinical trial not allowed

**NEI Vision Research Epidemiology Grant**

This FOA supports epidemiologic studies that utilize creative and innovative approaches to studying vision diseases and disorders with high public impact and whose findings will inform prevention and treatment strategies as well as basic sciences research.

**Application Due Dates:** Standard dates apply; **Expiration Date:** September 8, 2021

## NIH Funding Opportunities: Program Announcements (PA)

The following program announcements have standard due dates, unless otherwise noted.

[PA-18-849 \(R01\)](#); [PA-18-850 \(R21\)](#) – clinical trial optional

**Prevention Research in Mid-Life Adults**

Expiration Date: September 8, 2021

[PA-18-856 \(R01\)](#) – clinical trial not allowed

**Diet and Physical Activity Assessment Methodology**

Expiration Date: September 8, 2021

[PA-18-863 \(R01\)](#); [PA-18-862 \(R21\)](#); [PA-18-861 \(R03\)](#) – clinical trial optional

**Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention**

Expiration Date: January 2, 2022

[PA-18-876 \(R01\)](#) – clinical trial not allowed

**Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research**

Expiration Date: September 8, 2021

**Specific Due Dates:**

[PA-18-817 \(Admin Supplement\)](#) – clinical trial not allowed


**Administrative Supplements for Research on Dietary Supplements**

**Application Due Dates:** October 15, 2018; January 15, 2019; April 15, 2019; October 15, 2019; January 15, 2020; or April 15, 2020

[PA-18-818 \(Admin Supplement\)](#) – clinical trial not allowed

**Administrative Supplements for Validation Studies of Analytical Methods for Dietary Supplement Constituents**

**Application Due Dates:** October 15, 2018; January 15, 2019; April 15, 2019; October 15, 2019; January 15, 2020; or April 15, 2020



"There are those who work all day. Those who dream all day. And those who spend an hour dreaming before setting to work to fulfill those dreams. Go into the third category because there's virtually no competition."

-- Steven J Ross